|
Title
|
|
|
|
All eyes on the prefusion-stabilized F construct, but are we missing the potential of alternative targets for respiratory syncytial virus vaccine design?
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Respiratory Syncytial Virus (RSV) poses a significant global health concern as a major cause of lower respiratory tract infections (LRTIs). Over the last few years, substantial efforts have been directed towards developing vaccines and therapeutics to combat RSV, leading to a diverse landscape of vaccine candidates. Notably, two vaccines targeting the elderly and the first maternal vaccine have recently been approved. The majority of the vaccines and vaccine candidates rely solely on a prefusion-stabilized conformation known for its highly neutralizing epitopes. Although, so far, this antigen design appears to be successful for the elderly, our current understanding remains incomplete, requiring further improvement and refinement in this field. Pediatric vaccines still have a long journey ahead, and we must ensure that vaccines currently entering the market do not lose efficacy due to the emergence of mutations in RSV's circulating strains. This review will provide an overview of the current status of vaccine designs and what to focus on in the future. Further research into antigen design is essential, including the exploration of the potential of alternative RSV proteins to address these challenges and pave the way for the development of novel and effective vaccines, especially in the pediatric population. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Vaccines
| |
|
Publication
|
|
|
|
Basel
:
Mdpi
,
2024
| |
|
ISSN
|
|
|
|
2076-393X
| |
|
DOI
|
|
|
|
10.3390/VACCINES12010097
| |
|
Volume/pages
|
|
|
|
12
:1
(2024)
, p. 1-27
| |
|
Article Reference
|
|
|
|
97
| |
|
ISI
|
|
|
|
001151431200001
| |
|
Pubmed ID
|
|
|
|
38250910
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|